Clinical Trial

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Study acronym: ADAPTIVE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
Protocol Amendment History 6 changes
notable Trial sites expanded: 23 -> 30 locations 2026-08-13
critical Primary endpoint(s) modified 2026-05-28
notable Enrollment increased: 220 -> 405 participants 2026-05-28
minor Trial arms changed: 4 -> 9 2026-05-28
notable Primary completion pushed: 2026-11 -> 2027-12 2026-05-28
minor Completion pushed: 2027-10 -> 2028-08 2026-05-28
Trial Details
NCT Number NCT07037901
Lead Sponsor Inmagene LLC
Conditions Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Enrollment 405 participants
Start Date 2025-06-17
Primary Completion 2027-12 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-12